| Visionworks Inc | |
| 6555 E Southern Ave, Ste 2410, Mesa, Arizona 85206 | |
| (480) 985-7239 |
| Name | Visionworks Inc |
|---|---|
| Organization Name | Visionworks Inc |
| Location | 6555 E Southern Ave, Ste 2410, Mesa, Arizona 85206 |
| Type | Eyewear Supplier (Equipment, not the service) |
| Phone | (480) 985-7239 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Cephalon, Inc. announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase price paid at closing, inclusive of certain closing adjustments, was CHF 662.4 million (or approximately US$615.4 million). The purchase price is also subject to further post-closing working capital and net debt adjustments.
Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.
Researchers at University of Illinois Chicago are studying a novel approach to delivering care to those with moderate depression and anxiety: through artificial intelligence, or AI.
Findacure, a rare diseases charity based in Cambridge, saysrepurposing existing drugs to treat rare diseases will improve patient outcomes and save the NHS money.
› Verified 1 days ago
| NPI Number | 1053408344 |
| Organization Name | TOM SOWASH OD & ASSOCIATES |
| Doing Business As | EYEMASTERS |
| Type | Eyewear Supplier (Equipment, not the service) |
| Address | 6555 E Southern Ave, Suite 2410, Mesa, AZ 85206 |
| Phone Number | 480-985-7239 |
News Archive
Cephalon, Inc. announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase price paid at closing, inclusive of certain closing adjustments, was CHF 662.4 million (or approximately US$615.4 million). The purchase price is also subject to further post-closing working capital and net debt adjustments.
Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.
Researchers at University of Illinois Chicago are studying a novel approach to delivering care to those with moderate depression and anxiety: through artificial intelligence, or AI.
Findacure, a rare diseases charity based in Cambridge, saysrepurposing existing drugs to treat rare diseases will improve patient outcomes and save the NHS money.
› Verified 1 days ago
| NPI Number | 1578716908 |
| Organization Name | VISIONWORKS, INC |
| Doing Business As | VISIONWORKS |
| Type | Eyewear Supplier (Equipment, not the service) |
| Address | 6555 E Southern Ave, #2410, Mesa, AZ 85206 |
| Phone Number | 480-985-7239 |
News Archive
Cephalon, Inc. announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase price paid at closing, inclusive of certain closing adjustments, was CHF 662.4 million (or approximately US$615.4 million). The purchase price is also subject to further post-closing working capital and net debt adjustments.
Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.
Researchers at University of Illinois Chicago are studying a novel approach to delivering care to those with moderate depression and anxiety: through artificial intelligence, or AI.
Findacure, a rare diseases charity based in Cambridge, saysrepurposing existing drugs to treat rare diseases will improve patient outcomes and save the NHS money.
› Verified 1 days ago
News Archive
Cephalon, Inc. announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase price paid at closing, inclusive of certain closing adjustments, was CHF 662.4 million (or approximately US$615.4 million). The purchase price is also subject to further post-closing working capital and net debt adjustments.
Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.
Researchers at University of Illinois Chicago are studying a novel approach to delivering care to those with moderate depression and anxiety: through artificial intelligence, or AI.
Findacure, a rare diseases charity based in Cambridge, saysrepurposing existing drugs to treat rare diseases will improve patient outcomes and save the NHS money.
› Verified 1 days ago
Osco Drug #0980 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1951 W Baseline Rd, Mesa, Arizona 85202 Phone: (480) 456-4850 | |
Osco Drug #1002 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 9243 E Baseline Rd, Mesa, Arizona 85209 Phone: (480) 986-4660 | |
Osco Drug #1948 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 441 N Val Vista Dr, Mesa, Arizona 85213 Phone: (480) 830-5185 | |
Osco Drug #3989 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2727 N Power Rd, Mesa, Arizona 85215 Phone: (480) 396-3838 | |
Osco Pharmacy # 958 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 325 S Power Rd, Mesa, Arizona 85206 Phone: (480) 924-8928 |